List of works - Sidonie Lambert-Niclot

Anti-gp41 antibody levels reflect HIV viral suppression and cellular reservoir in long-term antiretroviral-treated trial participants

scientific article published on 01 May 2019

Antiretroviral combinations implicated in emergence of the L74I and L74V resistance mutations in HIV-1-infected patients

scientific article

Antiretroviral-Experienced HIV-1-Infected Patients Treated with Maraviroc: Factors Associated with Virological Response

scientific article published on 17 December 2014

Characterization of drug resistance and the defective HIV reservoir in virally suppressed vertically infected children in Mali

scientific article published on 19 February 2020

Description of the L76V resistance protease mutation in HIV-1 B and "non-B" subtypes

scientific article

Detection of HIV-1 RNA in seminal plasma samples from treated patients with undetectable HIV-1 RNA in blood plasma

article

Detection of HIV-1 RNA in seminal plasma samples from treated patients with undetectable HIV-1 RNA in blood plasma on a 2002-2011 survey

scientific article published in May 2012

Determinants of a Low CD4/CD8 Ratio in HIV-1-Infected Individuals Despite Long-term Viral Suppression

scientific article

Differential impact of APOBEC3-driven mutagenesis on HIV evolution in diverse anatomical compartments

scientific article published on February 2014

Direct quantification of cell-associated HIV DNA in isolated rectal and blood memory CD4 T cells revealed their similar and low infection levels in long-term treated HIV-infected patients

scientific article published in March 2013

Drug resistance and tropism as markers of the dynamics of HIV-1 DNA quasispecies in blood cells of heavily pretreated patients who achieved sustained virological suppression

scientific article published on 16 December 2015

E138K and M184I mutations in HIV-1 reverse transcriptase coemerge as a result of APOBEC3 editing in the absence of drug exposure

scientific article published in August 2012

Effect of antiretroviral drugs on the quality of semen

scientific article published in August 2011

Effect of therapeutic intensification followed by HIV DNA prime and rAd5 boost vaccination on HIV-specific immunity and HIV reservoir (EraMune 02): a multicentre randomised clinical trial.

scientific article published on 17 February 2015

Efficacy and safety of once-daily ritonavir-boosted atazanavir or darunavir in combination with a dual nucleos(t)ide analogue backbone in HIV-1-infected combined ART (cART)-naive patients with severe immunosuppression: a 48 week, non-comparative, ra

scientific article

Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136.

scientific article

Evaluation of a rapid diagnostic assay for detection of SARS CoV-2 antigen in nasopharyngeal swab

scientific article published on 13 May 2020

Evolution of the K65R, K103N and M184V/I reverse transcriptase mutations in HIV-1-infected patients experiencing virological failure between 2005 and 2010.

scientific article published on 7 June 2013

Factors Associated With Virological Failure in HIV-1–Infected Patients Receiving Darunavir/Ritonavir Monotherapy

article

Factors associated with a low HIV reservoir in patients with prolonged suppressive antiretroviral therapy

scientific article

Factors associated with proviral DNA HIV-1 tropism in antiretroviral therapy-treated patients with fully suppressed plasma HIV viral load: implications for the clinical use of CCR5 antagonists

scientific article

Factors associated with the selection of mutations conferring resistance to protease inhibitors (PIs) in PI-experienced patients displaying treatment failure on darunavir

scientific article

Frequency of amino acid changes associated with resistance to attachment inhibitor BMS-626529 in R5- and X4-tropic HIV-1 subtype B.

scientific article

Genetic barrier for attachment inhibitor BMS-626529 resistance in HIV-1 B and non-B subtypes

scientific article published on 30 September 2014

HIV Replication Is Not Controlled by CD8+ T Cells during the Acute Phase of the Infection in Humanized Mice

scientific article

HIV genetic diversity between plasma and cerebrospinal fluid in patients with HIV encephalitis

article

HIV-1 X4/R5 co-receptor in viral reservoir during suppressive HAART

article

HIV-1 genome is often defective in PBMCs and rectal tissues after long-term HAART as a result of APOBEC3 editing and correlates with the size of reservoirs

scientific article published on 11 June 2012

Historical HIV-RNA resistance test results are more informative than proviral DNA genotyping in cases of suppressed or residual viraemia

scientific article published on 26 January 2011

INSTI-Based Triple Regimens in Treatment-Naïve HIV-Infected Patients Are Associated With HIV-RNA Viral Load Suppression at Ultralow Levels

article

Impact of Adding Enfuvirtide to the Predictive Value of the Darunavir Genotypic Resistance Score

scientific article published on 01 May 2011

Impact of HIV-1 minority variants on the virus response to a rilpivirine-based first line regimen

scientific article published on 13 December 2017

Impact of gag mutations on selection of darunavir resistance mutations in HIV-1 protease

scientific article published in September 2008

Impact of lopinavir/ritonavir use on antiretroviral resistance in recent clinical practice

scientific article published on 25 June 2012

Low frequency of HIV-1 tropism evolution in patients successfully treated for at least 2 years

article

Low frequency of intermittent HIV-1 semen excretion in patients treated with darunavir-ritonavir at 600/100 milligrams twice a day plus two nucleoside reverse transcriptase inhibitors or monotherapy

scientific article published on 16 August 2010

Low-level HIV-1 viraemia in patients on HAART: risk factors and management in clinical practice

scientific article published on 28 April 2015

Mutations associated with virological response to darunavir/ritonavir in HIV-1-infected protease inhibitor-experienced patients

scientific article published on 15 January 2009

Neutrophils in antiretroviral therapy-controlled HIV demonstrate hyperactivation associated with a specific IL-17/IL-22 environment

scientific article published on 16 July 2014

New HIV-1 circulating recombinant form 94: from phylogenetic detection of a large transmission cluster to prevention in the age of geosocial-networking apps in France, 2013 to 2017

scientific article published on 01 September 2019

New Kaposi's sarcoma-associated herpesvirus variant in men who have sex with men associated with severe pathologies

scientific article published on 13 April 2020

New resistance mutations to nucleoside reverse transcriptase inhibitors at codon 184 of HIV-1 reverse transcriptase (M184L and M184T)

scientific article published on 27 November 2018

Pharmacokinetics, protein-binding-adjusted inhibitory quotients for atazanavir/ritonavir 300/100 mg in treatment-naïve HIV-infected patients

scientific article published in November 2010

Positive impact of HIV-1 gag cleavage site mutations on the virological response to darunavir boosted with ritonavir

scientific article published on 31 January 2011

Presence of HIV-1 R5 viruses in cerebrospinal fluid even in patients harboring R5X4/X4 viruses in plasma

scientific article

Primary genotypic resistance of HIV-1 to CCR5 antagonists in CCR5 antagonist treatment-naive patients

scientific article published in October 2008

Qualitative and quantitative HIV antibodies and viral reservoir size characterization in vertically infected children with virological suppression

scientific article published on 30 December 2016

Rapid plasma viral suppression in naive HIV-infected patients with high CD4 cells and low viraemia initiating a dual nucleoside reverse transcriptase inhibitor strategy: a proof-of-concept study

scientific article published on 22 July 2014

Resistant minority species are rarely observed in patients on darunavir/ritonavir monotherapy.

scientific article

Similar evolution of cellular HIV-1 DNA level in darunavir/ritonavir monotherapy versus triple therapy in MONOI-ANRS136 trial over 96 weeks

scientific article

Switching to darunavir/ritonavir 800/100 mg once-daily containing regimen maintains virological control in fully suppressed pre-treated patients infected with HIV-1.

scientific article published on 28 September 2012

Transient HIV-specific T cells increase and inflammation in an HIV-infected patient treated with nivolumab

scientific article published on April 2017

Treatment intensification followed by interleukin-7 reactivates HIV without reducing total HIV DNA: a randomized trial

scientific article published on January 2016

Treatment interruption in chronically HIV-infected patients with an ultralow HIV reservoir

scientific article

Ultradeep sequencing detection of the R263K integrase inhibitor drug resistance mutation

scientific article published on 14 January 2017

Ultrasensitive Human Immunodeficiency Virus Type 1 Viral Load as a Marker of Treatment Choice for Simplification Strategies

scientific article published on 01 November 2018

Usefulness of Kaposi sarcoma-associated herpesvirus (KSHV)-DNA viral load in whole blood for the diagnosis and monitoring of KSHV-associated diseases.

scientific article

Very early ART resulting in the absence of HIV-1 antibodies and in a sustained undetectable plasma HIV-1-RNA and proviral-DNA in an HLA-B*5701 and Δ32 heterozygote HIV-1-infected patient was not associated with functional cure

scientific article published on 19 September 2014

List of works by Sidonie Lambert-Niclot

Anti-gp41 antibody levels reflect HIV viral suppression and cellular reservoir in long-term antiretroviral-treated trial participants

Antiretroviral combinations implicated in emergence of the L74I and L74V resistance mutations in HIV-1-infected patients

Antiretroviral-Experienced HIV-1-Infected Patients Treated with Maraviroc: Factors Associated with Virological Response

Characterization of drug resistance and the defective HIV reservoir in virally suppressed vertically infected children in Mali

Description of the L76V resistance protease mutation in HIV-1 B and "non-B" subtypes

Detection of HIV-1 RNA in seminal plasma samples from treated patients with undetectable HIV-1 RNA in blood plasma

Detection of HIV-1 RNA in seminal plasma samples from treated patients with undetectable HIV-1 RNA in blood plasma on a 2002-2011 survey

Determinants of a Low CD4/CD8 Ratio in HIV-1-Infected Individuals Despite Long-term Viral Suppression

Differential impact of APOBEC3-driven mutagenesis on HIV evolution in diverse anatomical compartments

Direct quantification of cell-associated HIV DNA in isolated rectal and blood memory CD4 T cells revealed their similar and low infection levels in long-term treated HIV-infected patients

Drug resistance and tropism as markers of the dynamics of HIV-1 DNA quasispecies in blood cells of heavily pretreated patients who achieved sustained virological suppression

E138K and M184I mutations in HIV-1 reverse transcriptase coemerge as a result of APOBEC3 editing in the absence of drug exposure

Effect of antiretroviral drugs on the quality of semen

Effect of therapeutic intensification followed by HIV DNA prime and rAd5 boost vaccination on HIV-specific immunity and HIV reservoir (EraMune 02): a multicentre randomised clinical trial.

Efficacy and safety of once-daily ritonavir-boosted atazanavir or darunavir in combination with a dual nucleos(t)ide analogue backbone in HIV-1-infected combined ART (cART)-naive patients with severe immunosuppression: a 48 week, non-comparative, ra

Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136.

Evaluation of a rapid diagnostic assay for detection of SARS CoV-2 antigen in nasopharyngeal swab

Evolution of the K65R, K103N and M184V/I reverse transcriptase mutations in HIV-1-infected patients experiencing virological failure between 2005 and 2010.

Factors Associated With Virological Failure in HIV-1–Infected Patients Receiving Darunavir/Ritonavir Monotherapy

Factors associated with a low HIV reservoir in patients with prolonged suppressive antiretroviral therapy

Factors associated with proviral DNA HIV-1 tropism in antiretroviral therapy-treated patients with fully suppressed plasma HIV viral load: implications for the clinical use of CCR5 antagonists

Factors associated with the selection of mutations conferring resistance to protease inhibitors (PIs) in PI-experienced patients displaying treatment failure on darunavir

Frequency of amino acid changes associated with resistance to attachment inhibitor BMS-626529 in R5- and X4-tropic HIV-1 subtype B.

Genetic barrier for attachment inhibitor BMS-626529 resistance in HIV-1 B and non-B subtypes

HIV Replication Is Not Controlled by CD8+ T Cells during the Acute Phase of the Infection in Humanized Mice

HIV genetic diversity between plasma and cerebrospinal fluid in patients with HIV encephalitis

HIV-1 X4/R5 co-receptor in viral reservoir during suppressive HAART

HIV-1 genome is often defective in PBMCs and rectal tissues after long-term HAART as a result of APOBEC3 editing and correlates with the size of reservoirs

Historical HIV-RNA resistance test results are more informative than proviral DNA genotyping in cases of suppressed or residual viraemia

INSTI-Based Triple Regimens in Treatment-Naïve HIV-Infected Patients Are Associated With HIV-RNA Viral Load Suppression at Ultralow Levels

Impact of Adding Enfuvirtide to the Predictive Value of the Darunavir Genotypic Resistance Score

Impact of HIV-1 minority variants on the virus response to a rilpivirine-based first line regimen

Impact of gag mutations on selection of darunavir resistance mutations in HIV-1 protease

Impact of lopinavir/ritonavir use on antiretroviral resistance in recent clinical practice

Low frequency of HIV-1 tropism evolution in patients successfully treated for at least 2 years

Low frequency of intermittent HIV-1 semen excretion in patients treated with darunavir-ritonavir at 600/100 milligrams twice a day plus two nucleoside reverse transcriptase inhibitors or monotherapy

Low-level HIV-1 viraemia in patients on HAART: risk factors and management in clinical practice

Mutations associated with virological response to darunavir/ritonavir in HIV-1-infected protease inhibitor-experienced patients

Neutrophils in antiretroviral therapy-controlled HIV demonstrate hyperactivation associated with a specific IL-17/IL-22 environment

New HIV-1 circulating recombinant form 94: from phylogenetic detection of a large transmission cluster to prevention in the age of geosocial-networking apps in France, 2013 to 2017

New Kaposi's sarcoma-associated herpesvirus variant in men who have sex with men associated with severe pathologies

New resistance mutations to nucleoside reverse transcriptase inhibitors at codon 184 of HIV-1 reverse transcriptase (M184L and M184T)

Pharmacokinetics, protein-binding-adjusted inhibitory quotients for atazanavir/ritonavir 300/100 mg in treatment-naïve HIV-infected patients

Positive impact of HIV-1 gag cleavage site mutations on the virological response to darunavir boosted with ritonavir

Presence of HIV-1 R5 viruses in cerebrospinal fluid even in patients harboring R5X4/X4 viruses in plasma

Primary genotypic resistance of HIV-1 to CCR5 antagonists in CCR5 antagonist treatment-naive patients

Qualitative and quantitative HIV antibodies and viral reservoir size characterization in vertically infected children with virological suppression

Rapid plasma viral suppression in naive HIV-infected patients with high CD4 cells and low viraemia initiating a dual nucleoside reverse transcriptase inhibitor strategy: a proof-of-concept study

Resistant minority species are rarely observed in patients on darunavir/ritonavir monotherapy.

Similar evolution of cellular HIV-1 DNA level in darunavir/ritonavir monotherapy versus triple therapy in MONOI-ANRS136 trial over 96 weeks

Switching to darunavir/ritonavir 800/100 mg once-daily containing regimen maintains virological control in fully suppressed pre-treated patients infected with HIV-1.

Transient HIV-specific T cells increase and inflammation in an HIV-infected patient treated with nivolumab

Treatment intensification followed by interleukin-7 reactivates HIV without reducing total HIV DNA: a randomized trial

Treatment interruption in chronically HIV-infected patients with an ultralow HIV reservoir

Ultradeep sequencing detection of the R263K integrase inhibitor drug resistance mutation

Ultrasensitive Human Immunodeficiency Virus Type 1 Viral Load as a Marker of Treatment Choice for Simplification Strategies

Usefulness of Kaposi sarcoma-associated herpesvirus (KSHV)-DNA viral load in whole blood for the diagnosis and monitoring of KSHV-associated diseases.

Very early ART resulting in the absence of HIV-1 antibodies and in a sustained undetectable plasma HIV-1-RNA and proviral-DNA in an HLA-B*5701 and Δ32 heterozygote HIV-1-infected patient was not associated with functional cure